UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Registrant's telephone number, including area code: (617) 651-8851 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38978 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as spec ...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2021 Earnings Conference Call November 4, 2021 8:00 AM ET Company Representatives Bryan Stuart - President, Chief Executive Officer Chris Morabito - Chief Medical Officer Peter Thomson - Vice President of Finance & Accounting Judy Dunn - President of R&D Paul Bruno - Senior Director of Corporate Development Naomi Aoki - Senior Vice President of Corporate Communications, Investor Relations Conference Call Participants Dae Gon Ha - Stiefel Ted Tenthoff - Piper Sandl ...

WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the transition period from to Commission File Number: 001-38978 FULCRUM THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-4839948 (State or other j ...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q2 2021 Earnings Conference Call August 10, 2021 8:00 AM ET Company Participants Christi Waarich - Director, IR & Corporate Communications Bryan Stuart - President & CEO Chris Moxham - CSO Chris Morabito - CMO Conference Call Participants Ted Tenthoff - Piper Sandler Dae Gon Ha - Stiefel Joseph Schwartz - SVB Leerink Matthew Harrison - Morgan Stanley Tazeen Ahmad - Bank of America Judah Frommer - Credit Suisse Operator Good morning, and welcome to the Fulcrum Therape ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCRUM THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-4839948 (State or other jurisd ...

Fulcrum | --- | --- | --- | --- | |-------------------------------------------------------------------------|-------|-------|-------| | | | | | | | | | | | Regulating Gene Expression to Treat the Root Cause of Disease May 2021 | | | | | | | | | Disclaimer and Notice This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the development status of the Com ...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q1 2021 Earnings Conference Call May 6, 2021 8:00 AM ET Company Participants Christi Waarich - Director, Investor Relations & Corporate Communications Bryan Stuart - President & Chief Executive Officer Chris Moxham - Chief Scientific Officer Peter Thomson - Vice President, Finance & Accounting Conference Call Participants Kelly Girskis - SVB Leerink Ted Tenthoff - Piper Sandler Kostas Biliouris - Morgan Stanley Tazeen Ahmad - Bank of America Operator Good morning, a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCRUM THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Emerging growth company ☒ If an emerging ...

Fulcrum | --- | --- | --- | --- | --- | |---------------------------------------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | Regulating Gene Expression to Treat the Root Cause of Disease March 2021 | | | | | | | | | | | Disclaimer and Notice This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the dev ...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2020 Results Earnings Conference Call March 4, 2021 8:00 AM ET Company Participants Christi Waarich - Director, Investor Relations and Corporate Communications Robert Gould - President & CEO Bryan Stuart - Chief Operating Officer Chris Moxham - Chief Scientific Officer Peter Thomson - Vice President, Finance and Accounting Conference Call Participants Ted Tenthoff - Piper Sandler Joseph Schwartz - SVB Leerink Dae Gon Ha - Stifel Matthew Harrison - Morgan Stanley O ...